Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Derma Sciences Inc. Stories

2013-04-22 23:04:03

Derma Sciences, Inc. is pleased to announce that Ed Quilty, President & CEO of Derma Sciences, Inc. (NASDAQ: DSCI) will be presenting at the Taglich Brothers 10th Annual Small Cap Equity Conference May 7, 2013. New York, NY (PRWEB) April 22, 2013 Derma Sciences, Inc. is pleased to announce that Ed Quilty, President & CEO of Derma Sciences, Inc. (NASDAQ: DSCI) will be presenting at the Taglich Brothers 10th Annual Small Cap Equity Conference May 7, 2013. The Conference will take...

2010-07-14 16:34:00

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI) announces the following Webcast: What: LHA Life Sciences & Med Tech Day 2010 Presentation When: July 20, 2010 @ 11:30 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=160488 Live over the Internet --Simply log on to the web at How: the address above. Contact: Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com If you are unable to...

2010-06-09 07:17:00

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, has been awarded the Healthcare Common Procedural Coding System (HCPCS) code A6266 for its BIOGUARD(TM) Conforming Bandage. This code, which was awarded by the Centers for Medicare and Medicaid Services (CMS), is the same as that assigned for other antimicrobial large roll gauze dressings, and allows the Conforming Bandage to be...

2010-06-07 06:45:00

PRINCETON, N.J., June 7 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that its ALGICELL® Ag wound dressings have received a CE mark for use in the European Union. SGS Group, the world's largest Control and Inspection Company, supervised the assessment and certification process. The CE marking verifies that ALGICELL® Ag has met all relevant...

2010-06-03 13:33:00

PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that Edward J. Quilty, Chairman and CEO, will make a presentation regarding the business strategy and financial outlook of the Company at the Noble Financial Sixth Annual Equity Conference at 12:30pm EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida. The presentation will be webcast LIVE featuring...

2010-05-13 08:00:00

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months ended March 31, 2010. Highlights for First Quarter 2010: Net sales increased 23% to $12,844,382 versus $10,431,891 in first quarter 2009. Advanced wound care sales increased 70% to $2,281,564 versus $1,346,223 in first quarter 2009. Net loss was...

2010-05-12 06:49:00

PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it has established an international subsidiary, Derma Sciences Europe Limited, and will soon be opening an office near London, England. "Europe represents a substantial growth opportunity for Derma Sciences and is a logical next step in expanding our sales efforts," said Edward J. Quilty, Derma Sciences'...

2010-05-11 11:56:00

PRINCETON, N.J., May 11 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will present at the Rodman & Renshaw Annual Global Investment Conference. The Conference will take place May 16 - 18, 2010 at the Grosvenor House Hotel in London, UK. Edward J. Quilty, Chairman and CEO of Derma Sciences will present on Tuesday, May 18, 2010 at 10:40 am BST (5:40 am ET) in the Spencer Suite. Additional...

2010-05-04 06:49:00

PRINCETON, N.J., May 4 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the launch of its new XTRASORB(TM) Foam dressing. The dressing is the company's first novel entry in the $300 million foam wound dressing market. First sales are expected during the second quarter of 2010. The majority of chronic wounds tend to have moderate to heavy levels of wound fluid, which is best managed...

2010-05-03 08:33:00

PRINCETON, N.J., May 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, will hold a conference call on May 13, 2010 to discuss the results for the first quarter ended March 31, 2010. The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern Daylight Time). The results will be released at approximately 9:00 a.m. EDT that same day. To access the conference call, US-based listeners...